Skip to main content
. Author manuscript; available in PMC: 2021 Aug 14.
Published in final edited form as: Mol Cancer Ther. 2020 Sep 2;19(11):2319–2329. doi: 10.1158/1535-7163.MCT-20-0101

Figure 4: Menin inhibition increases gefitinib-induced autophagic flux.

Figure 4:

A) HT-29 cells treated for 72 hours, 10 μM gefitinib, 1 μM MI-2–2. B) HCT-15 cells treated for 72 hours, 10 μM gefitinib, 1 μM MI-2–2. C) HT-29 cells treated with varying concentrations of MI-2–2 for 48 hours, 10 μM gefitinib. D) HT-29 cells treated with varying concentrations of gefitinib for 48 hours, 1 μM MI-2–2. E) HT-29 cells treated for either 24 or 48 hours, 10 μM gefitinib, 1 μM MI-2–2. F) HT-29 cells treated for 8 or 24 hours, 10 μg/mL E64d, 10 μg/mL Pepstain A. G) HT-29 cells treated for 72 hours, 10 μM spautin-1. H) HT-29 cells treated for 72 hours, 5mM 3-MA. I) HT-29 cells transfected with GFP-LC3B were treated for 48 hours with images captured at 200X. 10 μM gefitinib, 1 μM MI-2–2.